BANK VONTOBEL/PUT/NOVO NORDISK ADR B/130/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 19:01:30 05/07/2024 BST | ||
| 0.31 EUR | -8.82% |
|
| Current month | +10.71% | ||
| 1 month | -16.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.31 | -8.82% |
| 04/07/24 | 0.34 | -15.00% |
| 03/07/24 | 0.4 | +37.93% |
| 02/07/24 | 0.29 | +26.09% |
| 01/07/24 | 0.23 | -17.86% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 07:01 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1G2L |
| ISIN | DE000VD1G2L0 |
| Date issued | 04/03/2024 |
| Strike | 130 $ |
| Maturity | 20/09/2024 (76 Days) |
| Parity | 10 : 1 |
| Emission price | 1.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.28 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.01 € |
| Spread % | 3.23% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
